1. Home
  2. RYTM vs WD Comparison

RYTM vs WD Comparison

Compare RYTM & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • WD
  • Stock Information
  • Founded
  • RYTM 2008
  • WD 1937
  • Country
  • RYTM United States
  • WD United States
  • Employees
  • RYTM N/A
  • WD N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • WD Finance: Consumer Services
  • Sector
  • RYTM Health Care
  • WD Finance
  • Exchange
  • RYTM Nasdaq
  • WD Nasdaq
  • Market Cap
  • RYTM 3.5B
  • WD 3.3B
  • IPO Year
  • RYTM 2017
  • WD 2010
  • Fundamental
  • Price
  • RYTM $56.07
  • WD $83.10
  • Analyst Decision
  • RYTM Strong Buy
  • WD Hold
  • Analyst Count
  • RYTM 10
  • WD 3
  • Target Price
  • RYTM $66.90
  • WD $106.67
  • AVG Volume (30 Days)
  • RYTM 380.5K
  • WD 220.3K
  • Earning Date
  • RYTM 02-26-2025
  • WD 02-13-2025
  • Dividend Yield
  • RYTM N/A
  • WD 3.21%
  • EPS Growth
  • RYTM N/A
  • WD 0.31
  • EPS
  • RYTM N/A
  • WD 3.19
  • Revenue
  • RYTM $112,530,000.00
  • WD $1,051,964,999.00
  • Revenue This Year
  • RYTM $66.58
  • WD N/A
  • Revenue Next Year
  • RYTM $44.63
  • WD $7.30
  • P/E Ratio
  • RYTM N/A
  • WD $26.20
  • Revenue Growth
  • RYTM 81.55
  • WD 5.57
  • 52 Week Low
  • RYTM $35.17
  • WD $82.97
  • 52 Week High
  • RYTM $68.58
  • WD $118.19
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 42.18
  • WD 27.93
  • Support Level
  • RYTM $56.03
  • WD $83.17
  • Resistance Level
  • RYTM $58.65
  • WD $96.00
  • Average True Range (ATR)
  • RYTM 1.87
  • WD 2.56
  • MACD
  • RYTM -0.27
  • WD -0.92
  • Stochastic Oscillator
  • RYTM 5.45
  • WD 1.00

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

About WD Walker & Dunlop Inc

Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company's products consist of first mortgage loans, second trust loans, supplemental financings, construction loans, mezzanine loans, and bridge/interim loans. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.

Share on Social Networks: